Expert Interview
Examining the potential of Sanofi's novel anti-CD40L antibody, frexalimab, in patients with relapsing multiple sclerosis with a neurologist
Ticker(s): SNYInstitution: Mount Sinai Medical Center
- Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis.
- Manages 1500 patients with Multiple Sclerosis.
- Research and clinical trial experience in emerging treatment options in Multiple Sclerosis; was among the first in the country involved with studies of Interferon beta-1b.
- Served as chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
